The Hindu Business Line : J&J to hold trials for new drug

JOHNSON & Johnson (J&J) is planning to conduct clinical trials of its new dapoxetine hydrochloride, a treatment for premature ejaculation, in India. Health Ministry officials said that the permission was granted last month to the company.

J&J has submitted the drug for approval to the US Food and Drug Administration and is optimistic with the trial reports from the US. According to international reports, if dapoxetine enters the market in early 2006, it will total $160 million in sales that year and will hit $500 million in sales in 2007. The patent for dapoxetine was originally held by Eli Lilly and was bought by PPD, Inc (a research organisation) in 2003. PPD then licensed the drug to ALZA Corp, a subsidiary of J&J.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Rainfall tapering off in north, northwest

High market prices affect open offers of MNCs

Petroleum Ministry not to intervene in levy of excise on LPG, kerosene

Breach of data security is a disaster waiting to happen in India — Use wiping tools, then destroy hard disk drive, say experts

Competition hits me-too brands of Viagra, Cialis

J&J to hold trials for new drug

Finance Ministry agrees to amend tax laws — Fund of Funds to be categorised into equity, debt

Oil issue may set the direction

Preparations on for issuing national identity cards